Does inhibition of constitutively active Stat3 reverse enzalutamide resistance in LNCaP derivative prostate cancer cells?
This study demonstrates that the autocrine IL-6 pathway induces enzalutamide resistance in prostate cancer cells via the constitutive activation of Stat3. Co-targeting IL6-Stat3 pathway with enzalutamide may be utilized for treatment of advanced prostate cancer.
Tumour diameter and decreased preoperative eGFR are independently correlated in patients with RCC.